Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPD CardioProtect
ISRCTN29148209Phase 2Active, not recruiting
- Sponsor
- Hull University Teaching Hospitals
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 2, randomised, single-blind trial of budesonide and BEVESPI AEROSPHERE in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Hull University Teaching Hospitals. Primary endpoint: Change in platelet activation by P-selectin expression. Started Sep 2024; status: active, not recruiting.
02
Drugs
budesonideBEVESPI AEROSPHERE
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ISRCTN29148209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN29148209.